{"podcast":{"title":"UBS Global Research Pod Hub","slug":"ubs-global-research-pod-hub-6511142","podcast_index_feed_id":6511142,"rss_url":"https://www.ubs.com/global/en/investment-bank/insights-and-data/global-research/_jcr_content/root/contentarea/mainpar/toplevelgrid_copy/col_1/responsivepodcast.itunes.xml","website_url":"https://www.ubs.com/global/en/investment-bank/insights-and-data/global-research.html","image_url":"https://www.ubs.com/content/dam/assets/ib/global/podcast/research-podcasts/ib-research-podcast-spotify.png","author":"UBS","episode_count":139,"summary":"Tune in to our episodes for insights on the topics that matter from our global economics, strategy and industry thought leaders at UBS","last_synced_at":null,"page_url":"https://stenobird.com/podcast/ubs-global-research-pod-hub-6511142"},"episode":{"title":"What is driving the comeback story in biopharma?","slug":"what-is-driving-the-comeback-story-in-biopharma","published_at":"2026-02-13T15:09:22+00:00","page_url":"https://stenobird.com/podcast/ubs-global-research-pod-hub-6511142/what-is-driving-the-comeback-story-in-biopharma","show_page_url":"https://stenobird.com/podcast/ubs-global-research-pod-hub-6511142","url":"https://www.ubs.com/content/dam/assets/ib/global/podcast/research-podcasts/mike-dimiter.mp3","audio_url":"https://www.ubs.com/content/dam/assets/ib/global/podcast/research-podcasts/mike-dimiter.mp3","summary":"With drug pricing cuts easing, investor interest is returning, driven by fresh innovation, active M&A, and rotation into a long undervalued sector. Dimiter Tassev, UBS Healthcare Advisory Sales Specialist, speaks with Michael Yee, Global Head of Biotechnology Research at UBS investment Bank, about the outlook for US biopharma. *(This information is subject to a disclaimer at the end of this podcast. Please ensure that you listen to the disclaimer and go to www.ubs.com for further information about UBS).","meta_description":"With drug pricing cuts easing, investor interest is returning, driven by fresh innovation, active M&A, and rotation into a long undervalued sector. Di…","key_points":[],"chapters":[],"topics":[],"duration_seconds":911,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/ubs-global-research-pod-hub-6511142/episodes/what-is-driving-the-comeback-story-in-biopharma/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/ubs-global-research-pod-hub-6511142/what-is-driving-the-comeback-story-in-biopharma.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}